-
Oil falls further on Mideast deal, but Fed outlook knocks equities
-
Mexico, Korea eye World Cup knockout berths
-
Range raises $8.3M Series A to unify treasury, risk and compliance across stablecoins and fiat
-
IAEA ready to help define 'concrete steps' to implement US-Iran deal
-
Ibrahima Konate signs four-year deal with Real Madrid
-
Hegseth tells NATO US will review force presence in Europe
-
Innovations on show at Paris Vivatech fest
-
Ukraine sets Moscow refinery ablaze in biggest attack in years
-
Bird flu kills 13,000 seal pups on remote Australian island
-
Oil prices sink further as Trump signs deal to reopen Hormuz
-
South Korean lawmakers launch probe into ballot paper shortages
-
Starmer rival seeks win in UK poll pivotal to PM's fate
-
Taiwan president says hopes for $14 bn US arms sale 'as soon as possible'
-
Why are Kenyan kids burning schools and killing their classmates?
-
New wave of anti-LGBTQ laws sweeps Africa
-
Ukraine hopes renewables can Russia-proof power grid
-
Jubilant New York on guard for Knicks parade
-
What we learned after the first round of World Cup games
-
New Zealander Manu has 'no fear' of Toulouse before Top 14 semi
-
Drastic restrictions on public transport take effect in Cuba
-
Pain-riddled South Korean man fights for right to die
-
Cuba approves economic reforms to boost private sector, investment: state TV
-
India learns to live with hotter summers
-
'Retired' Wallaby Slipper, 37, set for shock international comeback
-
EU wrestles over how to tackle China export flood
-
Tartan Army takes over Boston as Scotland fans relish World Cup return
-
Comedian Jordan Klepper wishes satire was harder in age of Trump
-
Robots pour cocktails and run marathons, but still can't multitask
-
Birthright citizenship helps spark US World Cup run
-
Ghana beat Panama 1-0 in World Cup opener after injury-time winner
-
Castro gives crucial backing to Cuba reforms
-
Tuchel team talk transformed 'nervy' England in World Cup win
-
Historic World Cup goal brings rare joy to DR Congo Ebola epicentre
-
Korea coach slams 'unfortunate' drone incident at training
-
Trump, Iran's president sign deal to end Mideast war
-
Kane double fires England World Cup bid as Ronaldo's Portugal stumble
-
Casemiro, Ancelotti's lieutenant and symbol of Brazil troubles
-
Qantas to launch non-stop Sydney-London flights in October 2027
-
Kane scores twice as England beat Croatia to launch World Cup charge
-
Danilo backs Brazil to get over World Cup 'fright'
-
Iran to dilute its enriched uranium under accord with US to end Mideast war
-
South Africa's Broos hits out at 'trash' talk, targets World Cup redemption
-
US Fed chair Warsh vows reforms as central bank signals rate hikes on horizon
-
US stocks fall, dollar rallies as Fed raises inflation forecast
-
No split loyalties for US star 'Jedi' Robinson
-
Czechs eye World Cup liftoff against South Africa
-
Lula jokes he is thinking of 'signing Messi' for Brazil
-
Borthwick plans to rest Itoje for England tour
-
Prince Harry and family to visit UK in July: media
-
Barbarians pick Vakatawa for South Africa match
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
J.Sauter--VB